Certara, Inc.
Financials
Valuation Metrics
Certara, Inc.'s Market Cap is $1.33B. At end of 2025 it was $1.41B. Ranked #2300 of 3,121 in US market (top 74%), #927 of 1,463 on NASDAQ (top 63%), #143 of 205 in Health Care Equipment & Services (top 70%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.33B | US#2,300/3,121 Sec#143/205 |
| Revenue | $408M | US#2,351/3,121 Sec#146/205 |
| Net Income | $-68M | US—/3,121 Sec—/205 |
| Total Assets | $1.40B | US#2,303/3,121 Sec#118/205 |
| Net Assets | $967M | US#1,788/3,121 Sec#95/205 |
| Employees | 1,515 | US#1,826/3,121 Sec#123/205 |
| Value | ||
| P/B | 1.38x | US#774/3,121 Sec#37/205 |
| P/S | 3.27x | US#1,818/3,121 Sec#127/205 |
| EV/EBITDA | 17.32x | US#1,746/3,121 Sec#78/205 |
| FCF Yield | 4.62% | US#1,494/3,121 Sec#74/205 |
| Profitability | ||
| ROE | -7.08% | US#2,311/3,121 Sec#127/205 |
| ROA | -4.89% | US#2,512/3,121 Sec#138/205 |
| Op. Margin | 1.86% | US#2,257/3,121 Sec#124/205 |
| Revenue Growth | 0.66% | US#2,200/3,121 Sec#162/205 |
| Earnings Growth | -957.07% | US#2,032/3,121 Sec#104/205 |
| Financial Health | ||
| Debt Ratio | 44.83% | US#506/3,121 Sec#55/205 |
| Total Debt | $292M | US#2,110/3,121 Sec#114/205 |
| FCF | $62M | US#1,909/3,121 Sec#115/205 |
| Cash | $184M | US#1,800/3,121 Sec#110/205 |
| Current Ratio | 2.55x | US#955/3,121 Sec#95/205 |
| Net Debt/EBITDA | 1.29x | US#1,083/3,121 Sec#64/205 |
| Dividend | ||
| Div. Yield | 0.00% | US—/3,121 Sec—/205 |
| Payout Ratio | 0.00% | US—/3,121 Sec—/205 |
| Performance | ||
| 1Y Return | -25.46% | US#2,536/3,121 Sec#168/205 |
| 1M Return | 7.12% | US#347/3,121 Sec#48/205 |
| From 52W High | -38.18% | US#2,405/3,121 Sec#160/205 |
| 1Y MDD | -67.06% | US#2,912/3,121 Sec#183/205 |
| Trading | ||
| Volume | 2,111,839 shares | US#790/3,121 Sec#43/205 |
| Trading Value | $18M | US#1,961/3,121 Sec#133/205 |
| Per Share | ||
| EPS | $-0.44 | US—/3,121 Sec—/205 |
| BPS | $6.21 | US#2,179/3,121 Sec#133/205 |
Company Info
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.